Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioharvest Sciences (BHST) Current Deferred Revenue (2023 - 2025)

Bioharvest Sciences has reported Current Deferred Revenue over the past 3 years, most recently at $492000.0 for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 45.7% year-over-year to $492000.0; the TTM value through Dec 2025 reached $492000.0, down 45.7%, while the annual FY2025 figure was $492000.0, 45.7% down from the prior year.
  • Current Deferred Revenue was $492000.0 for Q4 2025 at Bioharvest Sciences, up from $438000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $1.1 million in Q1 2025 and bottomed at $438000.0 in Q3 2025.
  • The 3-year median for Current Deferred Revenue is $906000.0 (2024), against an average of $797000.0.
  • Year-over-year, Current Deferred Revenue increased 26.18% in 2024 and then tumbled 45.7% in 2025.
  • Over 3 years, Current Deferred Revenue stood at $718000.0 in 2023, then increased by 26.18% to $906000.0 in 2024, then tumbled by 45.7% to $492000.0 in 2025.
  • The last three reported values for Current Deferred Revenue were $492000.0 (Q4 2025), $438000.0 (Q3 2025), and $990000.0 (Q2 2025) per Business Quant data.